⌕
Avalo Therapeutics · AVTX · Nasdaq
Tenet 55 · Mixed
Compare
$6.76+0.15%At closeTenet 55 · Mixed
$6.76+0.01 (+0.15%)
At close: Nov 20, 2026, 4:00 PM ET· Nasdaq · USD

Avalo Therapeutics (AVTX) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (37 new · 59 increased · 30 reduced · 14 closed · 23 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 52 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
share base unverified · 163 filers, Sep 30, 2026
# 13F FUNDS
163
13F VALUE
$1.1B
74.5M shares
Percent withheld: the raw figure is 128.9% of the implied share base, above the 105% ceiling that 13F double counting of shared or lent shares can explain, so the share base is unverified. The filer count, share total and dollar value are as filed and are unaffected.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Sep 30, 2026Jain RitadirectorAcquired · Grant / award1,322Stock Option (Right to Buy)$12.29↗
Sep 30, 2026Lind Kevin RobertdirectorAcquired · Grant / award1,352Stock Option (Right to Buy)$12.29↗
Sep 30, 2026Philip Ron MdirectorAcquired · Grant / award1,109Stock Option (Right to Buy)$12.29↗
Sep 16, 2026Sullivan Christopher RyanChief Financial OfficerAcquired · Option exercise12,394$9.88↗
Sep 16, 2026Sullivan Christopher RyanChief Financial OfficerDisposed · Open-market sale12,394$16.33↗
Sep 16, 2026Sullivan Christopher RyanChief Financial OfficerDisposed · Option exercise12,394Stock Option (Right to Buy)—↗
Sep 10, 2026Sullivan Christopher RyanChief Financial OfficerAcquired · Option exercise10,185$8.04↗
Sep 10, 2026Sullivan Christopher RyanChief Financial OfficerDisposed · Open-market sale10,185$17.62↗
Sep 10, 2026Sullivan Christopher RyanChief Financial OfficerDisposed · Option exercise10,185Stock Option (Right to Buy)—↗
Aug 28, 2026Doyle MittieChief Medical OfficerAcquired · Option exercise679$8.04↗
Aug 28, 2026Doyle MittieChief Medical OfficerDisposed · Open-market sale679$20.00↗
Aug 28, 2026Doyle MittieChief Medical OfficerDisposed · Option exercise679Stock Option (Right to Buy)—↗
Aug 18, 2026Sullivan Christopher RyanChief Financial OfficerAcquired · Option exercise31,031$9.88↗
Aug 18, 2026Sullivan Christopher RyanChief Financial OfficerDisposed · Open-market sale31,031$20.05↗
Aug 18, 2026Sullivan Christopher RyanChief Financial OfficerDisposed · Option exercise31,031Stock Option (Right to Buy)—↗
Aug 17, 2026Sullivan Christopher RyanChief Financial OfficerAcquired · Option exercise37,945$9.88↗
Aug 17, 2026Sullivan Christopher RyanChief Financial OfficerAcquired · Option exercise2,876$9.88↗
Aug 17, 2026Sullivan Christopher RyanChief Financial OfficerDisposed · Open-market sale37,945$19.85↗
Aug 17, 2026Sullivan Christopher RyanChief Financial OfficerDisposed · Open-market sale3,749$19.94↗
Aug 17, 2026Sullivan Christopher RyanChief Financial OfficerDisposed · Option exercise37,945Stock Option (Right to Buy)—↗

* Holdings as reported for Sep 30, 2026, 52 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold Avalo Therapeutics?

Avalo Therapeutics was held by 163 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.